TABLE 1.
Patient characteristics (complete cohort) according to deprivation quintiles of the European Deprivation Index (quintile 5 is the most deprived)
| All(N=8701) | Quintile 1 (N=1272) | Quintile 2 (N=1391) | Quintile 3 (N=1524) | Quintile 4 (N=1696) | Quintile 5 (N=2818) | |
|---|---|---|---|---|---|---|
| Patient characteristics | ||||||
| Age (y) | ||||||
| 18–30 | 685 (8%) | 88 (7%) | 98 (7%) | 110 (7%) | 143 (8%) | 246 (9%) |
| 30–60 | 4839 (56%) | 659 (52%) | 788 (57%) | 821 (54%) | 899 (53%) | 1672 (59%) |
| >60 | 3177 (37%) | 525 (41%) | 505 (36%) | 593 (39%) | 654 (39%) | 900 (32%) |
| Gender (female) | 3150 (36%) | 434 (34%) | 470 (34%) | 534 (35%) | 608 (36%) | 1104 (39%) |
| BMI (kg/m2) | ||||||
| <20 | 247 (3%) | 36 (3%) | 35 (3%) | 46 (3%) | 49 (3%) | 81 (3%) |
| 20–25 | 4203 (48%) | 638 (50%) | 675 (49%) | 719 (47%) | 854 (50%) | 1317 (47%) |
| >25 | 4251 (49%) | 598 (47%) | 681 (49%) | 759 (50%) | 793 (47%) | 1420 (50%) |
| Underlying nephropathy | ||||||
| Diabetic | 895 (10%) | 100 (8%) | 120 (9%) | 138 (9%) | 169 (10%) | 368 (13%) |
| Glomerulonephritis | 1979 (23%) | 309 (24%) | 352 (25%) | 368 (24%) | 401 (24%) | 549 (19%) |
| Interstitial nephritis | 789 (9%) | 102 (8%) | 128 (9%) | 144 (9%) | 152 (9%) | 263 (9%) |
| PKD (ref) | 1650 (19%) | 289 (23%) | 324 (23%) | 320 (21%) | 334 (20%) | 383 (14%) |
| Systemic disease | 302 (3%) | 43 (3%) | 48 (3%) | 60 (4%) | 59 (3%) | 92 (3%) |
| Uropathy | 204 (2%) | 29 (2%) | 37 (3%) | 36 (2%) | 47 (3%) | 55 (2%) |
| Vascular | 866 (10%) | 133 (10%) | 116 (8%) | 132 (9%) | 149 (9%) | 336 (12%) |
| Miscellaneous | 477 (5%) | 73 (6%) | 64 (5%) | 80 (5%) | 87 (5%) | 173 (6%) |
| Unknown | 1539 (18%) | 194 (15%) | 202 (15%) | 146 (16%) | 298 (18%) | 599 (21%) |
| Diabetes | 1466 (17%) | 190 (15%) | 228 (16%) | 228 (15%) | 266 (16%) | 554 (20%) |
| Cardiovascular disease | 2041 (23%) | 301 (24%) | 328 (24%) | 368 (24%) | 379 (22%) | 665 (24%) |
| Tobacco (smoker) | 4497 (52%) | 611 (48%) | 672 (48%) | 727 (48%) | 843 (50%) | 1351 (48%) |
| Hypertension | 5948 (68%) | 882 (69%) | 952 (68%) | 1036 (68%) | 1131 (67%) | 1947 (69%) |
| Positive hepatitis C serology | 222 (3%) | 26 (2%) | 35 (3%) | 18 (1%) | 41 (2%) | 102 (4%) |
| Positive CMV serology | 5147 (59%) | 602 (47%) | 702 (50%) | 818 (54%) | 983 (58%) | 2042 (72%) |
| Positive EBV serology | 8329 (96%) | 1213 (95%) | 1325 (95%) | 1452 (95%) | 1626 (96%) | 2713 (96%) |
| HLA antibody class I and/or II > 0% | 2309 (27%) | 317 (25%) | 347 (25%) | 395 (26%) | 438 (26%) | 812 (29%) |
| Blood group | ||||||
| B | 1043 (12%) | 134 (11%) | 149 (11%) | 172 (11%) | 162 (10%) | 426 (15%) |
| Others | 7658 (88%) | 1138 (89%) | 1242 (89%) | 1352 (89%) | 1534 (90%) | 2392 (85%) |
| Transplantation characteristics | ||||||
| Preemptive registration | 3026 (35%) | 532 (42%) | 547 (39%) | 573 (38%) | 584 (34%) | 790 (28%) |
| Preemptive transplantation | 1397 (16%) | 252 (20%) | 268 (19%) | 264 (17%) | 283 (17%) | 330 (12%) |
| Donor source | ||||||
| Living donor | 1225 (14%) | 209 (16%) | 220 (16%) | 219 (14%) | 251 (15%) | 326 (12%) |
| Of which PKT | 478 (39%) | 94 (45%) | 96 (44%) | 89 (41%) | 92 (37%) | 107 (33%) |
| Deceased donor | 7476 (86%) | 1063 (84%) | 1171 (84%) | 1305 (86%) | 1445 (85%) | 2492 (88%) |
| Of which PKT | 919 (12%) | 158 (15%) | 172 (15%) | 175 (13%) | 191 (13%) | 223 (9%) |
BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; PKD, polycystic kidney disease; PKT, preemptive kidney transplantation.